Susceptibility testing of fungi--current status and open questions.
The increase of fungal infections and the improvement of therapeutical options demand reliable antifungal susceptibility testing. In vitro susceptibility testing of fungi--in contrast to bacteria--is not yet established as a routine method. The NCCIS (National Committee for Clinical Laboratory Standards) guidelines for susceptibility testing of yeasts (and proposed for hyphomycetes) are most important for standardization. Meanwhile, essential parts of this test procedure are accepted, but it should still be improved. The concept of using only one test medium for all drugs and test organisms is not realized so far. There are also some test situations that prevent the NCCLS standard from being applied. Based on our experience, this article describes the NCCLS methods and their modifications. It places emphasis on lipophilic drugs showing controversies despite standardization. Furthermore, the prediction of MICs on the clinical outcome is discussed. Since there are some pitfalls in testing antifungals, this should be done in experienced laboratories only. The MIC has to be regarded as only one, but an important, factor in the management of fungal diseases. Host-, drug-, and pathogen-specific data should be considered simultaneously.
Seibold
Michael
M
Robert Koch-Institut, Mykologie, Nordufer 20, 13353 Berlin, Germany.
Tintelnot
Kathrin
K
D000818:Animals; D025141:Drug Resistance, Fungal; D005658:Fungi / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D003904:Mitosporic Fungi / Q000187:drug effects; D012015:Reference Standards; D015003:Yeasts / Q000187:drug effects